Cover Image
市場調查報告書

生物醫藥品受託製造市場:2015∼2025年

Biopharmaceutical Contract Manufacturing Market, 2015 - 2025

出版商 ROOTS ANALYSIS 商品編碼 329397
出版日期 內容資訊 英文 353 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
生物醫藥品受託製造市場:2015∼2025年 Biopharmaceutical Contract Manufacturing Market, 2015 - 2025
出版日期: 2015年05月05日 內容資訊: 英文 353 Pages
簡介

生物醫藥品的受託製造(CMO)設施的大半置於北美和歐洲。生物醫藥品CMO產業現在「一次購足」是標準,不過,在特定的業務中外包增加。由於生物醫藥品市場的迅速擴大與技術的進步,一般預期該市場以年率8.3%擴大。

本報告提供生物醫藥品受託製造市場現狀與未來預測的相關調查、2015∼2025年的預測、市場趨勢與今後的預測、參與企業簡介等彙整資料。

第1章 序論

第2章 摘要整理

第3章 簡介

  • 概要與背景
  • 生物醫藥品:概要
  • 生物醫藥品的製造
  • 表現系統
  • 生物醫藥品外包的需求
  • 一般外包的生物製造業活動
  • 主要的生物醫藥品CMO

第4章 生物醫藥品受託製造:先進地區

  • 本章概要
  • 生物醫藥品受託製造的發展
  • 美國的生物醫藥品的外包
  • 歐洲的生物醫藥品的外包
  • 日本:新的有希望國家
  • 已開發國家的法律規章比較

第5章 生物醫藥品受託製造:新興地區

  • 本章概要
  • 中國的生物醫藥品受託製造
  • 印度的生物醫藥品受託製造

第6章 競爭環境

  • 本章概要
  • 各地區分析
  • 各經營規模分析
  • 能力分析
  • 生物反應器的種類

第7章 生物醫藥品受託製造的利基領域

  • 本章概要
  • 抗體、藥物結合體
  • 雙特異性抗體治療藥
  • 基因治療

第8章 生技仿製藥的外包

  • 本章概要
  • 生技仿製藥:概要
  • 生技仿製藥的外包需求
  • 生技仿製藥CMO帶來的影響
  • 為了促進成本效益的生技仿製藥
  • 生技仿製藥市場上CMO和CRO的存在

第9章 近幾年趨勢

第10章 市場規模與預測

第11章 生物醫藥品CMO市場未來

  • 本章概要
  • 帶動成長的技術開發
  • 對利基市場區隔的著重
  • 生技仿製藥:大的機會
  • 促進投資活動的需求擴大
  • 外包預算的增額
  • CMO面臨能力變動的可能性
  • 新興市場的著重

第12章 SWOT分析

第13章 採訪原稿

第14章 結論

第15章 附錄

第16章 企業清單

目錄
Product Code: RA10037

Characterized by a rapidly expanding product pipeline and a capital intensive manufacturing business, the biopharmaceutical market is witnessing a growing trend towards contract manufacturing. In addition to serving as a cost-cutting tool, contract manufacturing provides several other advantages to biopharmaceutical companies including technical expertise, operational efficiency, regulatory support and the ability to focus on core competencies.Spanning multiple operations withinthe wider manufacturing processes, outsourcing is increasingly being viewed as a strategic imperative.

The current marketplace has the presence of over 160 biopharmaceutical CMOs, offering a multitude of services ranging from cell line development and API manufacturing to fill/ finish of the product. Lonza, Boehringer Ingelheim and FUJIFILM Diosynth Biotechnologies are amongst the leading companies in this market. In addition, there are several key players operating in emerging regions that contribute significantly to this market; examples include Kemwell Biopharma (India), Shasun Pharma (India) and WuXiAppTec (China).

Despite being surrounded with several challenges associated with cost and complexity in bio-manufacturing, the contract manufacturing market has witnessed considerable growth in the past few years. Driven by the strong growth in the biologics market and advancement in technologies, biopharmaceutical contract manufacturing is well positioned to achieve an accelerated growth in the coming years. An intensive framework of collaborations and investment activity further supports the optimistic growth outlook.

Synopsis:

The ‘Biopharmaceutical Contract Manufacturing Market, 2015 - 2025' report provides an extensive study of the contract manufacturing market for biopharmaceuticals. With biotechnology industry striving to maximize profits, outsourcing has emerged as an ever increasing trend. The study presents an in-depth analysis of a diverse set of biopharmaceutical CMOs on some of the key parameters such asgeographical location, scale of operation, type of biologics manufactured, expression systems, type of bioreactors used and fermentation capacity. In addition, it captures some of the potential growth areas which will likely present tremendous opportunities for biopharmaceutical CMOs and ensure an accelerated pace of growth. Some of the niche service areas include manufacturing of ADCs and bispecific antibodies. Specifically, these markets typify huge unmet manufacturing requirements and represent untapped areas of targeted therapy revenue making outsourcing an attractive option.

The report assesses the key drivers that have governed the evolution of biopharmaceutical contract manufacturing market over the past several years along with an elaborate discussion on the future trends that will shape the market in the coming years. One of the focus areas of this study is to estimate size of the future opportunity for biopharmaceutical CMOs market over the next decade, segmented on the basis of business operations, type of expression systems and key regions.

In addition, the study provides information on some of the most important aspects of biopharmaceutical outsourcing; these include growing collaborations, investment activity, technological advancements and development of biosimilars. In addition to some of the well-known benefits and a promising outlook, the study also highlights considerable challenges currently prevalent in the market. Examples include quality concerns, stringent regulations and lack of funding. Nevertheless, these challenges are paving the way for new strategies and technological improvements, which will indeed be advantageous in the long run.

The base year for the report is 2014; the report provides market forecasts for the period 2015 - 2025. The research, analysis and insights presented in this report is backed by a deep understanding of key insights gathered both from secondary and primary research.

Example Highlights

  • 1. North America and Europe are the predominant regions where majority of the production facilities of biopharmaceutical CMOs are located. Of the 160 CMOs we studied, 80 have presence in multiple locations in the US. In Europe, the other major hub for CMOs, Germanyand the UK have presence of over 20 CMOs. Companies have also gradually moved their focus to developing countries in order to take advantage of the relatively lower costs.
  • 2. With respect to the bio-manufacturing capabilities of contract manufacturers, majority of the CMOs currently are capable of manufacturing proteins and antibodies; mammalian based manufacturing represents the predominantly used production method and will continue to achieve a relatively highergrowth rate.
  • 3. In terms of analysis by scale of operation, majority of the biopharmaceutical CMOs have the capability to operate on clinical as well as commercial scale. Out of 153 CMOs evaluated for this exercise, over 70% have the provision for both clinical and commercial stage manufacturing.
  • 4. Although the ‘one stop shop' model is steadily gaining pace in the biopharmaceutical CMO industry, certain operations are witnessing an increased extent of outsourcing. Fill/ finish operations represents one of the most heavily outsourced operations; owing to the requirement of specialized technologies and technical expertise, this segment is projected to be outsourced significantly in the near future.
  • 5. Certain niche segments within bio-manufacturing which have garnered the interest of biopharmaceutical CMOs include manufacturing of ADCs, bispecific antibodies and gene therapy; these markets, characterized by an untapped potential and optimistic growth prospects will continue to benefit from an increasing presence of CMOs. In addition, the emerging biosimilars industry represents another key demand sector for biopharmaceutical CMOs.
  • 6. The highly competitive market landscape is abuzz with an intensive framework of growing investment activities and collaborations. In addition, technological advancements including the use of disposable technologies is another key bio-manufacturing trend that is emblematic of the current market intensity.
  • 7. Driven by the rapidly expanding biopharmaceutical market and technological advancements, we expect the overall market to grow at an annualized rate of 8.3%. The rate of growth is likely to vary significantly across different segments / activities and across geographical regions.

Research Methodology

Most of the data presented in this report has been gathered by secondary research. We have also conducted interviews with experts in the area (academia, industry, medical practice and other associations) to solicit their opinions on emerging trends in the market. This is primarily useful for us to draw out our own opinion on how the market will shape up across different regions and drug segments. Where possible, the available data has been checked for accuracy from multiple sources of information.

The secondary sources of information include

  • Annual reports
  • Investor presentations
  • SEC filings
  • Industry databases
  • News releases from company websites
  • Government policy documents
  • Other analysts' opinion reports

While the focus has been on forecasting the market over the coming ten years, the report also provides our independent view on various technological and non-commercial trends emerging in the industry. This opinion is solely based on our knowledge, research and understanding of the relevant market gathered from various secondary and primary sources of information.

Chapter Outlines

Chapter 2 provides an executive summary of the insights captured in our research. The summary offers a high level view on where the biopharmaceutical contract manufacturing market is headed in the mid-long term.

Chapter 3 provides a general overviewon biopharmaceuticals along with manufacturing procedures and use of expression systems. We have also explained the need for biopharmaceutical outsourcing and identified the commonly outsourced bio-manufacturing activities.

Chapter 4 highlights the trends, regulatory landscape and key players of the two leading biopharmaceutical contract manufacturing destinations, the US and Europe. The chapter also provides the US and Europe sub-market forecast segmented on the basis of type of business operations and expression systems.

Chapter 5 details biopharmaceutical contract manufacturing activities in China and India, providing information on regulatory framework, growth drivers, challenges along with a high-level view on production capabilities of some the key players of each of these countries. The chapter provides the sub-market forecast in each of the countries by type of business operations and expression systems.

Chapter 6 provides a comprehensive view on the global landscape of biopharmaceutical CMOs. An in-depth review including regional distribution, analysis by scale of operation, type of biologics manufactured and expression systems has been covered in this chapter. The chapter provides additional information on the production capabilities of the CMOs on type of bioreactor, mode of bioreactor and fermentation capacity.

Chapter 7 focuses on some of the niche sectors of biopharmaceutical outsourcing; these include ADCs, bispecific antibodies and gene therapy. The chapter provides a detailed market review, including information on the pipeline, partnerships, investments and the presence of CMOs in each of these areas.

Chapter 8 focuses on outsourcing of biosimilars, a major growth opportunity for biopharmaceutical CMOs. The chapter provides an overview on biosimilars and CMOs that are actively involved in the biosimilars market.

Chapter 9 analyses the recent developments in the biopharmaceutical CMO market. It contains information about the investments and partnerships that have happened in the past few years, along with an analysis of the trends that have been observed over the years. It also contains a brief section on the technological advancements which have recently shaped the market.

Chapter 10 presents the detailed forecast for biopharmaceutical contract manufacturing segmented by type of business (API and FDF), type of expression systems and key geographies. Due to the uncertain nature of the market, we have presented three different growth tracks outlined as conservative, base and optimistic scenarios.

Chapter 11 highlights additional dimensions such as rising outsourcing budgets, capacity fluctuations and shift towards strategic partneringthat will likely govern the growth and evolution of biopharmaceutical contract manufacturing market in the future.

Chapter 12 provides a SWOT analysis capturing the key elements likely to influence future growth.

Chapter 13 summarises the overall report. In this chapter, we provide a recap of the key takeaways and our independent opinion based on the research and analysis described in previous chapters.

Chapter 14 is a collection of transcripts of interviews conducted during the course of this study. Examples of companies interviewed are FUJIFILM Diosynth Technologies, Goodwin Biotechnology, Rentschler, Piramal Healthcare, Catalent and Novasep.

Chapter 15 is an appendix which provides tabulated data and numbers for all the figures provided in the report.

Chapter 16 is an appendix which provides a list of companies and organizations mentioned in the report.

Table of Contents

1. PREFACE

  • 1.1. Scope of the Report
  • 1.2. Research Methodology
  • 1.3. Chapter Outlines

2. EXECUTIVE SUMMARY

3. Introduction

  • 3.1. Context and Background
  • 3.2. Biopharmaceuticals: An Overview
  • 3.3. Manufacturing of Biopharmaceuticals
  • 3.4. Expression Systems
    • 3.4.1. Bacterial Protein ExpressionSystem
    • 3.4.2. Yeast Protein Expression System
    • 3.4.3. Mammalian Protein Expression System
    • 3.4.4. Insect Protein Expression System
    • 3.4.5. Plant Protein Expression System
  • 3.5. Need for Biopharmaceutical Outsourcing
  • 3.6. Commonly Outsourced Biomanufacturing Activities
  • 3.7. Selection of Biopharmaceutical CMOs

4. BIOPHARMACEUTICAL CONTRACT MANUFACTURING: DEVELOPED REGIONS

  • 4.1. Chapter Overview
  • 4.2. The Evolution of Biopharmaceutical Contract Manufacturing
  • 4.3. Biopharmaceutical Outsourcing in the US
    • 4.3.1. The Draft Guidance: Contract Manufacturing Arrangements for Drugs - Quality Agreements
  • 4.3.1.1. Definition of ‘Who' and ‘What' of Contract Manufacturing
  • 4.3.1.2. Quality Agreement
    • 4.3.2. US Biopharmaceutical CMOs: Overview and Capabilities
      • 4.3.2.1. Patheon
        • 4.3.2.1.1. Company Overview
        • 4.3.2.1.2. Financial Performance
        • 4.3.2.1.3. Services
        • 4.3.2.1.4. Partnerships
        • 4.3.2.1.5. Expansions
        • 4.3.2.1.6. Other Developments
        • 4.3.2.1.7. Future Outlook
      • 4.3.2.2. Catalent
        • 4.3.2.2.1. Company Overview
        • 4.3.2.2.2. Financial Performance
        • 4.3.2.2.3. Services
        • 4.3.2.2.4. Partnerships
        • 4.3.2.2.5. Approvals
        • 4.3.2.2.6. Expansions
        • 4.3.2.2.7. Future Outlook
      • 4.3.2.3. Baxter BioPharma Solutions
        • 4.3.2.3.1. Company Overview
        • 4.3.2.3.2. Financial Performance
        • 4.3.2.3.3. Services
        • 4.3.2.3.4. Partnerships
        • 4.3.2.3.5. Expansions
      • 4.3.2.4. AMRI
        • 4.3.2.4.1. Company Overview
        • 4.3.2.4.2. Financial Performance
        • 4.3.2.4.3. Services
        • 4.3.2.4.4. Expansions
        • 4.3.2.4.5. Future Outlook
      • 4.3.2.5. Cytovance Biologics
        • 4.3.2.5.1. Company Overview
        • 4.3.2.5.2. Services
        • 4.3.2.5.3. Partnerships
        • 4.3.2.5.4. Expansions
        • 4.3.2.5.5. Other Developments
    • 4.3.3. The US: Biopharmaceutical Sub-Market Forecast, 2015-2025
      • 4.3.3.1. The US Biopharmaceutical CMO Market Forecast: Distribution by Type of Business Operation
      • 4.3.3.2. The US Biopharmaceutical CMO Market Forecast: Distribution by Expression Systems
  • 4.4. Biopharmaceutical Outsourcing in Europe
    • 4.4.1. Biopharmaceutical Outsourcing: US vs. Europe
    • 4.4.2. EMA's cGMP Regulations
    • 4.4.3. European Biopharmaceutical CMOs: Overview and Capabilities
      • 4.4.3.1. Boehringer Ingelheim BioXcellence
        • 4.4.3.1.1. Company Overview
        • 4.4.3.1.2. Financial Performance
        • 4.4.3.1.3. Services
        • 4.4.3.1.4. Partnerships
        • 4.4.3.1.5. Expansions
        • 4.4.3.1.6. Future Outlook
      • 4.4.3.2. Lonza
        • 4.4.3.2.1. Company Overview
        • 4.4.3.2.2. Financial Performance
        • 4.4.3.2.3. Services
        • 4.4.3.2.4. Partnerships
        • 4.4.3.2.5. Expansions
        • 4.4.3.2.6. Future Outlook
      • 4.4.3.3. FUJIFILM Diosynth Biotechnologies
        • 4.4.3.3.1. Company Overview
        • 4.4.3.3.2. Financial Performance
        • 4.4.3.3.3. Services
        • 4.4.3.3.4. Partnerships
        • 4.4.3.3.5. Expansions
        • 4.4.3.3.6. Developments
        • 4.4.3.3.7. Future Outlook
      • 4.4.3.4. RentschlerBiotechnologie
        • 4.4.3.4.1. Company Overview
        • 4.4.3.4.2. Services
        • 4.4.3.4.3. Expansions
        • 4.4.3.4.4. Future Outlook
      • 4.4.3.5. Celonic
        • 4.4.3.5.1. Company Overview
        • 4.4.3.5.2. Services
        • 4.4.3.5.3. Partnerships
        • 4.4.3.5.4. Expansions
        • 4.4.3.5.5. Developments
    • 4.4.4. Europe: Biopharmaceutical Sub-Market Forecast, 2015-2025
      • 4.4.4.1. Europe Biopharmaceutical CMO Market Forecast: Distribution by Type of Business Operation
      • 4.4.4.2. Europe Biopharmaceutical CMO Market Forecast: Distribution by Expression Systems
      • 4.4.4.3. Europe Biopharmaceutical CMO Market Forecast: Distribution by Country
  • 4.5. Japan: A New and Promising Player
  • 4.6. Comparison of Regulatory Landscape in Developed Nations
    • 4.6.1. Requirement of Written Quality Agreements
    • 4.6.2. Regulatory Considerations During Clinical Development

5. BIOPHARMACEUTICAL CONTRACT MANUFACTURING: EMERGING REGIONS

  • 5.1. Chapter Overview
  • 5.2. Biopharmaceutical Contract Manufacturing in China
    • 5.2.1. Regulatory Scenario in China
    • 5.2.2. Challenges Faced by Chinese Biopharmaceutical CMOs
    • 5.2.3. Growing Investments in Biopharmaceutical Contract Manufacturing in China
    • 5.2.4. Chinese Biopharmaceutical CMOs: Overview and Capabilities
      • 5.2.4.1. AutekBio
      • 5.2.4.2. WuXiAppTec
    • 5.2.5. China: Biopharmaceutical Sub-Market Forecast, 2015-2025
      • 5.2.5.1. Chinese Biopharmaceutical CMO Market Forecast: Distribution by Type of Business Operation
      • 5.2.5.2. Chinese Biopharmaceutical CMO Market Forecast: Distribution by Expression Systems
  • 5.3. Biopharmaceutical Contract manufacturing in India
    • 5.3.1. Regulatory Scenario in India
    • 5.3.2. Challenges Faced by Indian Biopharmaceutical CMOs
    • 5.3.3. Indian Biopharmaceutical CMOs: Overview and Capabilities
      • 5.3.3.1. Kemwell Biopharma
      • 5.3.3.2. Shasun Pharma
      • 5.3.3.3. Intas Pharmaceuticals
      • 5.3.3.4. Syngene
      • 5.3.3.5. Piramal Healthcare Pharma Solutions
      • 5.3.13. India: Biopharmaceutical Sub-Market Forecast, 2015-2025
        • 5.3.13.1. Indian Biopharmaceutical CMO Market Forecast: Distribution by Type of Business Operation
        • 5.3.13.2. Indian Biopharmaceutical CMO Market Forecast: Distribution by Expression Systems

6. COMPETITIVE LANDSCAPE

  • 6.1. Chapter Overview
  • 6.2. Biopharmaceutical CMOs: Regional Analysis
  • 6.3. Biopharmaceutical CMOs: Analysis by Scale of Operation
  • 6.4. Biopharmaceutical CMOs: Capability Analysis
    • 6.4.1. Distribution by Type of Biologic Molecule
    • 6.4.2. Distribution By Expression Systems
  • 6.5. Biopharmaceutical CMOs: Type of Bioreactor

7. NICHE SECTORS IN BIOPHARMACEUTICAL CONTRACT MANUFACTURING

  • 7.1. Chapter Overview
  • 7.2. Antibody Drug Conjugates (ADCs)
    • 7.2.1. A Healthy Pipeline Demands In-House or Contract Manufacturing Capabilities
    • 7.2.2. Limited Number of Companies are Providing ADC Technology
    • 7.2.3. Steps Involved in Manufacturing an ADC
    • 7.2.4. Challenges Facing the ADC Manufacturers
    • 7.2.5. Extent of In-house Manufacturing
    • 7.2.6. Presence of Contract Manufacturers
      • 7.2.6.1. Linkers
      • 7.2.6.2. Cytotoxins
      • 7.2.6.3. Conjugation
    • 7.2.7. CMOs Investing to Increase Their ADC Capabilities Enabling Them to Tap the Growing Demand for Contract Manufacturing
    • 7.2.8. Contract Manufacturers Collaborating to Provide ADC Capabilities
  • 7.3. Bispecific Antibody Therapeutics
    • 7.3.1. The Bispecific Advantage
    • 7.3.2. Bispecific Antibody Formats
    • 7.3.3. A Healthy Pipeline of Bispecific Antibodies Has Drugs Spread Across Different Phases of Clinical Development
    • 7.3.4. Bispecific Antibody Production: Technology Providers
    • 7.3.5. Presence of Contract Manufacturers
  • 7.4. Gene Therapy
    • 7.4.1. A Highly Populated Pipeline Demands Appropriate Manufacturing Capabilities

8. OUTSOURCING OF BIOSIMILARS

  • 8.1. Chapter Overview
  • 8.2. Biosimilars: An Overview
  • 8.3. Need for Outsourcing Biosimilars
  • 8.4. Impact of Biosimilars on the CMOs
  • 8.5. Biosimilars to Drive Cost Effectiveness
  • 8.6. Presence of CMOs and CROs in the Biosimilars Market

9. RECENT DEVELOPMENTS

  • 9.1. Chapter Overview
  • 9.2. CMO Investments in New Facilities and Facility Expansions
    • 9.2.1. Growing Number of Investments Over the Years
    • 9.2.2. FUJIFILM Diosynth Biotechnologies Leads the Investments Activity
  • 9.2.3. Distribution of Investments by Type
  • 9.3. Deals and Partnerships
    • 9.3.1. Analysis by Type of Partnership
    • 9.3.2. Growing Trend of Partnerships
  • 9.4. Technological Advancements
    • 9.4.1. Adoption of Single-use Technologies
    • 9.4.2. Process Analytical Technology
    • 9.4.3. Continuous Processing
    • 9.4.4. Quality by Design in Bio-processing

10. MARKET SIZING AND FORECAST

  • 10.1. Context and Background
  • 10.2. Outsourcing in Biopharmaceutical Industry
  • 10.3. Forecast Methodology
  • 10.4. Biopharmaceutical API Contract Manufacturing Market, 2015 - 2025
  • 10.5. Biopharmaceutical FDF Contract Manufacturing Market, 2015 - 2025
  • 10.6. Overall Biopharmaceutical Contract Manufacturing Market, 2015 - 2025
  • 10.7. Biopharmaceutical Contract Manufacturing Market: Distribution By Expression Systems
  • 10.8. Biopharmaceutical Contract Manufacturing Market: Distribution By Region

11. FUTURE OF BIOPHARMACEUTICAL CMO MARKET

  • 11.1. Chapter Overview
  • 11.2. Technological Developments to Drive Growth
  • 11.3. Focus on Niche Segments
  • 11.4. Biosimilars: A Major opportunity for CMOs
  • 11.5. Growing Demand to Spur Investment Activity
  • 11.6. Outsourcing Budgets on Rise
  • 11.7. Shift TowardsaStrategic Partnering
  • 11.8. CMOs May Face Capacity Fluctuations
  • 11.9. Focus on Emerging Markets

12. SWOT ANALYSIS

  • 12.1. Chapter Overview
  • 12.2. Strengths
  • 12.3. Weaknesses
  • 12.4. Opportunities
  • 12.5. Threats

13. INTERVIEW TRANSCRIPTS

  • 13.1. Interview 1: FUJIFILM Diosynth Biotechnologies, Stephen Taylor, Senior Vice President Commercial
  • 13.2. Interview 2: Goodwin Biotechnology, David C. Cunningham, Director of Marketing and Communications
  • 13.3. Interview 3: RentschlerBiotechnologie, Dr. Birgit Schwab, Senior Manager Strategic Marketing
  • 13.4. Interview 4: Piramal Healthcare, Dr. Mark Wright, Site Head, Grangemouth
  • 13.5. Interview 5: Catalent Pharma Solutions, Stacy McDonald, Group Product Manager & Jennifer L. Mitcham, Director - Business Development
  • 13.6. Interview 6: Novasep Synthesis, Kevin Daley, Market Director Pharmaceuticals

14. CONCLUSION

  • 14.1. Biomanufacturing: A Profitable Segment for CMOs
  • 14.2. Key Industry Drivers and Challenges
  • 14.3. US and Europe will Remain the Key Manufacturing Sites
  • 14.4. A Multi-billion Dollar Rapidly Expanding Market
  • 14.5. Concluding Remarks

15. APPENDICES

16. LIST OF COMPANIES

List of Figures:

  • Figure 3.1: Types of Expression Systems
  • Figure 3.2: Commonly Outsourced Biomanufacturing Operations
  • Figure 4.1: US Biopharmaceutical Contract Manufacturing Market: Growth Drivers and Challenges
  • Figure 4.2: Patheon: Service Portfolio
  • Figure 4.3: Patheon: Revenues, 2009 - 2013 (USD million)
  • Figure 4.4: Patheon: Revenues by Business Divisions (USD million)
  • Figure 4.5: Patheon: Revenue Break-up for CMO (USD million, Percentage)
  • Figure 4.6: Catalent: Service Portfolio
  • Figure 4.7: Catalent: Revenues, 2010 - 2014 (USD million)
  • Figure 4.8: Catalent: Revenues by Business Divisions, 2014 (USD million)
  • Figure 4.9: Baxter BioPharma Solutions: Service Portfolio
  • Figure 4.10: Baxter Biopharma Solutions: Revenues, 2011 - 2014 (USD million)
  • Figure 4.11: AMRI: Service Portfolio
  • Figure 4.12: AMRI: Revenues, 2010 - 2014 (USD million)
  • Figure 4.13: AMRI: Revenues by Business Divisions, 2014 (USD million)
  • Figure 4.14: Cytovance Biologics: Service Portfolio
  • Figure 4.15: US Biopharmaceutical CMO Market by Type of Business Operation, 2015-2025: Base Scenario (USD billion)
  • Figure 4.16: US Biopharmaceutical CMO Market by Expression Systems, 2015-2025: Base Scenario (USD billion)
  • Figure 4.17: European Biopharmaceutical Contract Manufacturing Market: Growth Drivers and Challenges
  • Figure 4.18: BioXcellence: Service Portfolio
  • Figure 4.19: Boehringer Ingelheim: Revenues, 2009 - 2013 (EUR million)
  • Figure 4.20: Boehringer Ingelheim: Revenues by Business Divisions (EUR million)
  • Figure 4.21: Lonza: Service Portfolio
  • Figure 4.22: Lonza: Revenues, 2010 - 2014 (CHF million)
  • Figure 4.23: Lonza: Revenues by Business Divisions, 2014 (CHF million)
  • Figure 4.24: FUJIFILM Diosynth Biotechnologies: Service Portfolio
  • Figure 4.25: FUJIFILM Group: Revenues, 2010 - 2014 (JPY billion)
  • Figure 4.26: FUJIFILM Holdings: Revenues by Business Divisions, 2014 (JPY billion)
  • Figure 4.27: RentschlerBiotechnologie: Service Portfolio
  • Figure 4.28: Celonic: Service Portfolio
  • Figure 4.29: Europe Biopharmaceutical CMO Market by Type of Business Operation, 2015-2025: Base Scenario (USD billion)
  • Figure 4.30: Europe Biopharmaceutical CMO Market by Expression Systems, 2015-2025: Base Scenario (USD billion)
  • Figure 4.31: Europe Biopharmaceutical CMO Market: Distribution by EU5 Countries
  • Figure 4.32: Europe Biopharmaceutical CMO Market by Country, 2015-2025: Base Scenario (USD billion)
  • Figure 5.1: Chinese CMO Market: Growth Drivers
  • Figure 5.2: AutekBio: Service Portfolio
  • Figure 5.3: Chinese Biopharmaceutical CMO Market by Type of Business Operation, 2015-2025: Base Scenario (USD billion)
  • Figure 5.4: Chinese Biopharmaceutical CMO Market by Expression Systems, 2015-2025: Base Scenario (USD billion)
  • Figure 5.5: Indian CMO Market: Growth Drivers
  • Figure 5.6: Kemwell Biopharma: Partnerships and Expansions
  • Figure 5.7: Shasun Pharma: Revenues by Geography, 2013-14 (INR billion)
  • Figure 5.8: Biocon: Revenues by Business Divisions: 2014 (INR million)
  • Figure 5.9: Piramal: Partnerships and Investments
  • Figure 5.10: Indian Biopharmaceutical CMO Market by Type of Business Operation, 2015-2025: Base Scenario (USD billion)
  • Figure 5.11: Indian Biopharmaceutical CMO Market by Expression Systems, 2015-2025: Base Scenario (USD billion)
  • Figure 6.1: Biopharmaceutical CMOs: Geographical Location
  • Figure 6.2: Biopharmaceutical CMOs: Regional Distribution
  • Figure 6.3: Biopharmaceutical CMOs: Distribution by Scale of Operation
  • Figure 6.4: Biopharmaceutical CMOs: Distribution by Type of Biologic Molecule
  • Figure 6.5: Biopharmaceutical CMOs: Distribution by Expression Systems
  • Figure 6.6: Single Use Bioreactors: Advantages and Disadvantages
  • Figure 7.1: Companies Active in the ADC Market: Number of Molecules in Development (Clinical and Marketed)
  • Figure 7.2: Bispefic Antibody Pipeline Analysis: By Phase of Development
  • Figure 7.3: Gene Therapy Pipeline Analysis: By Phase of Development
  • Figure 7.4: Contract Manufacturing in Gene Therapy: By Capability
  • Figure 7.5: Contract Manufacturing in Gene Therapy: By Location
  • Figure 8.1: Biosimilars: Definition
  • Figure 9.1: Biopharmaceutical CMOs: Cumulative Investments by Year, 2009-2014
  • Figure 9.2: Biopharmaceuticals: Leading players by Investments
  • Figure 9.3: Distribution of Investments by Type
  • Figure 9.4: Biopharmaceuticals Agreements: Distribution by Type of Partnership
  • Figure 9.5: Biopharmaceuticals: Cumulative Partnerships by Year, Pre 2010 - 2014
  • Figure 9.6: Process Analytical Technology: Advantages
  • Figure 9.7: Continuous Processing: Key Advantages
  • Figure 10.1: Outsourced Segments in Biopharmaceutical Industry
  • Figure 10.2: Biopharmaceutical API Manufacturing Market, 2015 - 2025: Base Scenario (USD billion)
  • Figure 10.3: Biopharmaceutical FDF Manufacturing Market, 2015 - 2025: Base Scenario (USD billion)
  • Figure 10.4: Overall Biopharmaceutical Contract Manufacturing Market by Type of Business Operation, 2015 - 2025: Base Scenario (USD billion)
  • Figure 10.5: Overall Biopharmaceutical Contract Manufacturing Market by Expression Systems, 2015-2025: Base Scenario (USD billion)
  • Figure 10.6: Biopharmaceutical Contract Manufacturing Market: Regional Distribution, 2015, 2020 and 2025
  • Figure 12.1: Numbers of Biologics Approved by the USFDA, 2009-2014
  • Figure 12.2: Top Selling Biologics: Estimated Patent Expiry
  • Figure 14.1: Biopharmaceutical Contract Manufacturing: Key Growth Drivers and Challenges
  • Figure 14.2 Biopharmaceutical Contract Manufacturing Market (USD Billion) Forecast: 2015, 2020 and 2025

List of Tables:

  • Table 4.1: Patheon: Capacity for Sterile Formulations Filling
  • Table 4.2: Patheon: Facility Sites and Segments
  • Table 4.3: Catalent: Manufacturing and Laboratory Facilities
  • Table 4.4: Baxter BioPharma Solutions: Facility Sites and Manufacturing Services
  • Table 4.5: AMRI: Manufacturing and Laboratory Facilities
  • Table 4.6: FDA's Quality Agreement vs EMA's cGMP Regulations: Comparison
  • Table 4.7: BioXcellence: Facility Sites and Manufacturing Functions
  • Table 4.8: Lonza: Custom Development and Custom Manufacturing Sites
  • Table 4.9: Lonza: Mammalian Biopharmaceutical Facilities along with their Scale of Operation and Capacities
  • Table 4.10: FUJIFILM Diosynth: Upstream Capacity and Downstream Capabilities
  • Table 4.11: FUJIFILM Diosynth: Upstream Capacity in Mammalian Cell Culture
  • Table 4.12: Celonic: Custom Development and Custom Manufacturing Sites
  • Table 5.1: Kemwell Biopharma: Facility Sites and their Functions
  • Table 5.2: Shasun: Facility Sites and their Functions
  • Table 5.3: Intas: Facility Sites and their Functions
  • Table 5.4: Piramal: Facility Sites and their Functions
  • Table 6.1: Biopharmaceutical CMOs: Scale of Operation
  • Table 6.2: Biopharmaceutical CMOs: Type of Biologics
  • Table 6.3: Biopharmaceutical CMOs: Analysis by Expression Systems
  • Table 6.4: Biopharmaceutical CMOs: Analysis by Type of Bioreactor
  • Table 7.1: ADC Molecules in Preclinical Development/Discovery Phase
  • Table 7.2: List of Contract Manufacturers and Their Capabilities in ADC Manufacturing
  • Table 7.3: ADC CMOs: Investments
  • Table 7.4: ADC CMOs: Partnerships
  • Table 7.5: List of Bispecific Antibodies in Preclinical Development/ Discovery Stage
  • Table 7.6: Bispecific Antibodies: List of Technology Platforms
  • Table 7.7: Contract Manufacturing Organisations with Bispecific Antibody Capabilities: Screening, Expression or Purification
  • Table 7.8: Contract Manufacturers in Gene Therapy
  • Table 8.1: Contract Service Providers in Biosimilars
  • Table 9.1: Biopharmaceutical CMOs: Investments, 2009-2014
  • Table 9.2: Biopharmaceutical CMOs: Deals and Partnerships, 2004-2014
  • Table 12.1: Biopharmaceutical Contract Manufacturing: SWOT Analysis
  • Table 14.1: Patheon: Revenues, 2009-2013 (USD million)
  • Table 14.2: Patheon: Revenues by Business Divisions (USD million)
  • Table 14.3: Patheon: Revenue Break-up for CMO, 2013 (USD million, Percentage)
  • Table 14.4: Catalent: Revenues, 2010 - 2014 (USD million)
  • Table 14.5: Catalent: Revenues by Business Divisions, 2014 (USD million)
  • Table 14.6: Baxter Biopharma Solutions: Revenues, 2011-2014 (USD million)
  • Table 14.7: AMRI: Revenues, 2010 - 2014 (USD million)
  • Table 14.8: AMRI: Revenues by Business Divisions, 2014 (USD million)
  • Table 14.9: US Biopharmaceutical CMO Market by Type of Business Operation, 2015-2025: Base Scenario (USD billion)
  • Table 14.10: US Biopharmaceutical CMO Market by Type of Business Operation, 2015-2025: Conservative Scenario (USD billion)
  • Table 14.11: US Biopharmaceutical CMO Market by Type of Business Operation, 2015-2025: Optimistic Scenario (USD billion)
  • Table 14.12: US Biopharmaceutical CMO Market by Expression Systems, 2015-2025: Base Scenario (USD billion)
  • Table 14.13: US Biopharmaceutical CMO Market by Expression Systems, 2015-2025: Conservative Scenario (USD billion)
  • Table 14.14: US Biopharmaceutical CMO Market by Expression Systems, 2015-2025: Optimistic Scenario (USD billion)
  • Table 14.15: Boehringer Ingelheim: Revenues, 2009-2013 (EUR million)
  • Table 14.16: Boehringer Ingelheim: Revenues by Business Divisions, 2013 (EUR million)
  • Table 14.17: Lonza: Revenues, 2010 - 2014 (CHF Million)
  • Table 14.18: Lonza: Revenues by Business Divisions, 2014 (CHF million)
  • Table 14.19: FUJIFILM Group: Revenues, 2010 - 2014 (JPY Billion)
  • Table 14.20: Fujifilm Group: Revenues by Business Divisions, 2014 (JPY Billion)
  • Table 14.21: Europe: Biopharmaceutical CMO Market by Type of Business Operation, 2015-2025: Base Scenario (USD billion)
  • Table 14.22: Europe: Biopharmaceutical CMO Market by Type of Business Operation, 2015-2025: Conservative Scenario (USD billion)
  • Table 14.23: Europe Biopharmaceutical CMO Market by Type of Business Operation, 2015-2025: Optimistic Scenario (USD billion)
  • Table 14.24: Europe: Biopharmaceutical CMO Market by Expression Systems, 2015-2025: Base Scenario (USD billion)
  • Table 14.25: Europe: Biopharmaceutical CMO Market by Expression Systems, 2015-2025: Conservative Scenario (USD billion)
  • Table 14.26: Europe: Biopharmaceutical CMO Market by Expression Systems, 2015-2025: Optimistic Scenario (USD billion)
  • Table 14.27: Europe Biopharmaceutical CMO Market: Distribution by Countries
  • Table 14.28: Europe Biopharmaceutical CMO Market by Country, 2015-2025: Base Scenario (USD billion)
  • Table 14.29: Chinese Biopharmaceutical CMO Market by Type of Business Operation, 2015-2025: Base Scenario (USD billion)
  • Table 14.30: Chinese Biopharmaceutical CMO Market by Type of Business Operation, 2015-2025: Conservative Scenario (USD billion)
  • Table 14.31: Chinese Biopharmaceutical CMO Market by Type of Business Operation, 2015-2025: Optimistic Scenario (USD billion)
  • Table 14.32: Chinese Biopharmaceutical CMO Market by Expression Systems, 2015-2025: Base Scenario (USD billion)
  • Table 14.33: Chinese Biopharmaceutical CMO Market by Expression Systems, 2015-2025: Conservative Scenario (USD billion)
  • Table 14.34: Chinese Biopharmaceutical CMO Market by Expression Systems, 2015-2025: Optimistic Scenario (USD billion)
  • Table 14.35: Shasun Pharma: Revenues by Geography, 2013-14 (INR million)
  • Table 14.36: Biocon Revenues by Business Segments: 2014 (INR million)
  • Table 14.37: Indian Biopharmaceutical CMO Market by Type of Business Operation, 2015-2025: Base Scenario (USD billion)
  • Table 14.38: Indian Biopharmaceutical CMO Market by Type by Business Operation, 2015-2025: Conservative Scenario (USD billion)
  • Table 14.39: Indian Biopharmaceutical CMO Market by Type of Business Operation, 2015-2025: Optimistic Scenario (USD billion)
  • Table 14.40: Indian Biopharmaceutical CMO Market by Expression Systems, 2015-2025: Base Scenario (USD billion)
  • Table 14.41: Indian Biopharmaceutical CMO Market by Expression Systems, 2015-2025: Conservative Scenario (USD billion)
  • Table 14.42: Indian Biopharmaceutical CMO Market by Expression Systems, 2015-2025: Optimistic Scenario (USD billion)
  • Table 14.43: Biopharmaceutical CMOs: Regional Distribution
  • Table 14.44: Biopharmaceutical CMOs: Distribution by Scale of Operation
  • Table 14.45: Biopharmaceutical CMOs: Distribution by Type of Biologic Molecule
  • Table 14.46: Biopharmaceutical CMOs: Distribution by Expression Systems
  • Table 14.47: Biopharmaceutical CMOs: Analysis by Type of Bioreactor
  • Table 14.48: Companies Active in the ADC Market: Number of Molecules in Development (Clinical and Marketed)
  • Table 14.49: Bispecific Antibody Market, Pipeline Drugs: By Phase of Development
  • Table 14.50: Gene Therapy Pipeline Analysis: Distribution by Phase of Development
  • Table 14.51: Contract Manufacturing in Gene Therapy: By Capability
  • Table 14.52: Contract Manufacturing in Gene Therapy: By Location
  • Table 14.53: Biopharmaceutical CMOs: Cumulative Investments by Year, 2009-2014
  • Table 14.54: Biopharmaceuticals: Leading players by Investments
  • Table 14.55: Distribution of Investments by Type
  • Table 14.56: Biopharmaceuticals: Distribution by Type of Partnership
  • Table 14.57: Biopharmaceuticals: Cumulative Partnerships by Year, Pre 2010 - 2014
  • Table 14.58: Biopharmaceutical API Manufacturing Market, 2015 - 2025: Base Scenario (USD billion)
  • Table 14.59: Biopharmaceutical API Manufacturing Market, 2015 - 2025: Conservative Scenario (USD billion)
  • Table 14.60: Biopharmaceutical API Manufacturing Market, 2015 - 2025: Optimistic Scenario (USD billion)
  • Table 14.61: Biopharmaceutical FDF Manufacturing Market, 2015 - 2025: Base Scenario (USD billion)
  • Table 14.62: Biopharmaceutical FDF Manufacturing Market, 2015 - 2025: Conservative Scenario (USD billion)
  • Table 14.63: Biopharmaceutical FDF Manufacturing Market, 2015 - 2025: Optimistic Scenario (USD billion)
  • Table 14.64: Overall Biopharmaceutical Contract Manufacturing Market, 2015 - 2025: Base Scenario (USD billion)
  • Table 14.65: Overall Biopharmaceutical Contract Manufacturing Market, 2015 - 2025: Conservative Scenario (USD billion)
  • Table 14.66: Overall Biopharmaceutical Contract Manufacturing Market, 2015 - 2025: Optimistic Scenario (USD billion)
  • Table 14.67: Overall Biopharmaceutical Contract Manufacturing Market: Distribution by Expression Systems, 2015-2025: Base Scenario (USD billion)
  • Table 14.68: Overall Biopharmaceutical Contract Manufacturing Market: Distribution by Expression Systems, 2015-2025: Conservative Scenario (USD billion)
  • Table 14.69: Overall Biopharmaceutical Contract Manufacturing Market: Distribution by Expression Systems, 2015-2025: Optimistic Scenario (USD billion)
  • Table 14.70: Biopharmaceutical Contract Manufacturing Market: Regional Distribution, 2015, 2020 and 2025
  • Table 14.71: Numbers of Biologics Approved by the USFDA, 2009-2014

List of Companies:

The following companies and organizations have been mentioned in this report.

  • 1. 3P Biopharmaceuticals
  • 2. AAIPharma Services
  • 3. AbbVie
  • 4. AERAS
  • 5. Affinity Life Sciences, Inc.
  • 6. Ajinomoto Althea Inc.
  • 7. Aldevron
  • 8. Alliance Medical Products (Siegfried)
  • 9. Alpax Pharmaceuticals
  • 10. Amega Biotech
  • 11. Apotex Fermentation Inc.
  • 12. Asahi Glass Company, Ltd.
  • 13. AutekBio, Inc.
  • 14. Avecia
  • 15. Avesta Biotherapeutics and Research
  • 16. Avid Bioservices, Inc.
  • 17. Batavia Bioservices
  • 18. Bavarian Nordic GmbH
  • 19. Baxter BioPharma Solutions
  • 20. Bharat Biotech
  • 21. BIBITEC GmbH
  • 22. Binex Co. Ltd.
  • 23. Bio Elpida
  • 24. Bio-Concept
  • 25. BioConnection
  • 26. Bioconvergence
  • 27. Biomay AG
  • 28. BIOMEVA GmbH
  • 29. Biopharmaceutical Development Program - Frederick National Laboratory for Cancer Research (FNLCR)
  • 30. BioReliance
  • 31. BioSynergy
  • 32. Biotechnique
  • 33. Biotechpharma UAB
  • 34. BioVectra Inc.
  • 35. Biovian Ltd.
  • 36. BioVolutions
  • 37. BioXcellence (Boehringer Ingelheim)
  • 38. Cantab Biopharmaceuticals Ltd
  • 39. Catalent
  • 40. Cellca GmbH
  • 41. Celonic AG
  • 42. Center for Biocatalysis and Bioprocessing, The University of Iowa
  • 43. Cerbios Pharma
  • 44. ChemPartner
  • 45. CMC Biologics
  • 46. Cobra Biologics
  • 47. Cognate BioServices
  • 48. Concord Biotech Limited
  • 49. Cook Pharmica LLC
  • 50. Creative Biolabs
  • 51. Cytovance Biologics, Inc.
  • 52. Dalton Pharma Services
  • 53. Development Center for Biotechnology, Taiwan
  • 54. DM Bio (Dong-A meiji)
  • 55. Emergent Biosolutions
  • 56. Eucodis Bioscience
  • 57. Eurogentec Biologics
  • 58. Florida Biologix
  • 59. Formatech, Inc.
  • 60. Fujifilm Diosynth Biotechnologies
  • 61. Fujirebio Europe B.V.
  • 62. Gala Biotech (Catalent subsidiary)
  • 63. Genhelix (Mabxience group)
  • 64. GlaxoSmithKline Biopharmaceuticals
  • 65. Glycotope Group
  • 66. Goodwin Biotechnology, Inc.
  • 67. Grand River Aseptic Manufacturing
  • 68. Hisun Pharmaceuticals USA
  • 69. Hong Kong Institute of Biotechnology
  • 70. Hospira One 2 One
  • 71. IDT Biologika GmbH
  • 72. Inno Biologics Sdn. Bhd.
  • 73. Innovent Biologics, Inc.
  • 74. Intas Pharmaceuticals
  • 75. Integrity Bio
  • 76. Irvine Pharmaceutical Services
  • 77. KABS Pharmaceutic Services
  • 78. KBI BioPharma, Inc.
  • 79. Kemwell Biopharma Pvt Ltd
  • 80. Lampire Biological Laboratories
  • 81. LFB Biomanufacturing
  • 82. Lonza
  • 83. Lyophilization Services of New England.
  • 84. Mabion
  • 85. Maine Biotechnology Services, Inc.
  • 86. Mass Biologics
  • 87. MBI International
  • 88. Medicago
  • 89. Menarini Biotech S.r.l.
  • 90. Meridian Life Science, Inc.
  • 91. MiltenyiBiotec
  • 92. Mycenax Biotech
  • 93. Neuland Laboratories Limited
  • 94. NextarChempharma Ltd.
  • 95. Norwegian Institute of Public Health
  • 96. Nova Laboratories Ltd.
  • 97. Novasep
  • 98. Novozyme
  • 99. Novozymes Biopharma
  • 100. Octoplus
  • 101. Omnia Biologics
  • 102. OsoBio (AMRI)
  • 103. PacificGMP
  • 104. Paragon Bioservices
  • 105. Patheon (unit of DPx Holdings)
  • 106. Pfizer CentreSource
  • 107. PharmaSynth
  • 108. PharmedArtis GmbH
  • 109. Phyton Biotech
  • 110. Piramal Pharma Solutions
  • 111. Plasmid Factory
  • 112. Polymun Scientific
  • 113. Premas Biotech
  • 114. ProBioGen AG
  • 115. Progenitor Cell Therapy, LLC
  • 116. Promab Biotechnologies Inc.
  • 117. ProvantageBiodevelopment Center
  • 118. PX' Therapeutics
  • 119. Pyramid Labs
  • 120. QuaDPharma, LLC
  • 121. Reliance Life Sciences
  • 122. RentschlerBiotechnologie GmbH
  • 123. Richter-HELM Biotec GmbH
  • 124. SAFC Inc
  • 125. Samsung Biologics
  • 126. Sandoz
  • 127. Sanofi CEPiA
  • 128. Sanquin Pharmaceutical Servives
  • 129. Scil Proteins
  • 130. Shasun
  • 131. SICOR Biotech UAB (Teva)
  • 132. Statens Serum Institut (only API)
  • 133. Symbiosis Pharmaceutical Services
  • 134. SynCo Bio Partners
  • 135. Syngene
  • 136. Sypharma Pty Ltd
  • 137. Therapure Biopharma Inc.
  • 138. Thermo Fisher Scientific
  • 139. Toyobo Biologics, Inc.
  • 140. University of Nebraska - Biological Process Development Facility
  • 141. Vetter Pharma International GmbH
  • 142. VGXI Inc.
  • 143. Vibalogics
  • 144. Vista Biologicals Corp.
  • 145. Vivalis SA
  • 146. Wacker Biotech GmbH
  • 147. WaismanBiomanufacturing
  • 148. Walter Reed Pilot Biproduction facility
  • 149. Wockhardt Limited
  • 150. WRAIR Pilot Bioproduction Facility
  • 151. WuXiApptec, Inc.
  • 152. Xcelience
  • 153. BioPharmaceuticals Australia
  • 154. BioMARC
  • 155. Biovest International
  • 156. Enteris Biopharma
  • 157. HALIX
  • 158. BioGenomics
  • 159. Celltech Biologics
  • 160. BioIntermediair
  • 161. Damon Biotech
  • 162. Corning BioPro
  • 163. Biochemie
  • 164. Bristol Myers Squibb
  • 165. Nicholas laboratories
  • 166. Sumitra Pharmaceuticals
  • 167. Sanofi Aventis
  • 168. Roche
  • 169. Seattle Genetics
  • 170. AstellasPharma
  • 171. Pfizer
  • 172. Immunogen
  • 173. Immunomedics
  • 174. Amgen
  • 175. Millennium
  • 176. Celldex
  • 177. Progenics
  • 178. Genmab
  • 179. Bayer
  • 180. Biotest
  • 181. StemCentrx
  • 182. Viventia
  • 183. Ambrx
  • 184. Zhejiang Medicine Co.
  • 185. Oxford BioTherapeutics
  • 186. Novartis
  • 187. AbGenomics
  • 188. ADC Therapeutics
  • 189. Affinicon
  • 190. Allozyne
  • 191. AvidBiologics
  • 192. Daiichi Sankyo
  • 193. Eli Lilly
  • 194. Endo Pharmaceuticals
  • 195. Esperance Pharmaceuticals
  • 196. Intellect Neurosciences
  • 197. Merck
  • 198. Heidelberg Pharma
  • 199. National Research Council Canada
  • 200. Philochem
  • 201. Carbogen Amcis
  • 202. Mersana
  • 203. EMD Serono
  • 204. Serina Therapeutics
  • 205. Scripps Research Institute
  • 206. ADC Biotechnology
  • 207. Affimed
  • 208. Baliopharm
  • 209. OncoMed
  • 210. Celgene
  • 211. Zyngenia
  • 212. PharmAbcine
  • 213. Lindis Biotech
  • 214. Trion
  • 215. Merus
  • 216. MacroGenics
  • 217. Takeda
  • 218. ImClone Systems
  • 219. Synergys Biotherapeutics
  • 220. Glenmark Pharmaceuticals
  • 221. NovImmune
  • 222. Numab
  • 223. Synimmune
  • 224. F-star
  • 225. MediaPharma
  • 226. Alligator Bioscience
  • 227. Gilead
  • 228. Sorrento Therapeutics
  • 229. Xencor
  • 230. Dutalys
  • 231. Sea Lane Biotechnologies
  • 232. Zymeworks
  • 233. Ganymed Pharmaceuticals
  • 234. BioLineRx
  • 235. Protheragen
  • 236. Sutro Biopharma
  • 237. Fabion Pharmaceuticals
  • 238. Ho Research Consortium
  • 239. Paktis Antibody Services GmbH
  • 240. Beijing ABT Genetic Engineering Technology Co.
  • 241. International Joint Cancer Institute
  • 242. Military Medical University
  • 243. Institute of Immunology
  • 244. Trion Pharma
  • 245. Ablynx
  • 246. Active Biotech
  • 247. Adimab
  • 248. AstraZeneca
  • 249. Biogen-Idec
  • 250. Biotecnol
  • 251. Bicycle Therapeutics
  • 252. Epigen Biotech
  • 253. French National Centre for Scientific Research - Université de Toulouse
  • 254. Fusimab
  • 255. Genentech
  • 256. Merrimack
  • 257. Molecular Partners AG
  • 258. Regeneron Pharmaceuticals
  • 259. Receptor Logic
  • 260. UCB
  • 261. ZymoGenetics
  • 262. Zyngenia
  • 263. Cellular Therapeutics Ltd.
  • 264. Great Ormond Street Hospital
  • 265. Center for Cell & Gene Therapy
  • 266. King's College London
  • 267. Louisiana Gene Therapy Research Consortium
  • 268. Nature Technology Corporation
  • 269. Novacep Biopharmaceutical
  • 270. NHS Blood and Transplant
  • 271. Puresyn
  • 272. University of Oxford Clinical BioManufacturingFacility
  • 273. Vecura
  • 274. VGXI, Inc.
  • 275. Biocon
  • 276. Cellitron
  • 277. Harvest Moon
  • 278. Parexel
  • 279. Quintiles
  • 280. ZydusCadila
  • 281. WIL Research
  • 282. Symbiosis, the Analytical Company
  • 283. Blue Stream Laboratories
  • 284. Charles River Laboratories
  • 285. Covance, Inc.
  • 286. Eurofins Central Global Laboratory
  • 287. Frontage Laboratories, Inc.
  • 288. IDDI
  • 289. INC Research, LLC
  • 290. Intertek
  • 291. MPI Research
  • 292. SGS Life Science Services
  • 293. Celladon
  • 294. GlycoVaxyn AG
  • 295. MGC Pharma
  • 296. Sanofi-Aventis' Recherche and Development
  • 297. Transporin
  • 298. KalonBiotherpeutics
  • 299. AdAlta
  • 300. Valerion Therapeutics
  • 301. Voyager Therapeutics
  • 302. Evolva Holding
  • 303. OncoSynergy
  • 304. Redwood Bioscience Inc,
  • 305. Celladon Corporation
  • 306. Gallus BioPharmaceuticals
  • 307. Merck Millipore
  • 308. Minomic International Ltd.
  • 309. MorphoSys
  • 310. Lentigen Corporation
  • 311. INVISTA
  • 312. Insmed Inc.
  • 313. AMYRA
  • 314. Zhejiang HISUN Pharmaceuticals Co. Ltd.
  • 315. Aspyrian Therapeutics
  • 316. DSM Pharmaceutical Products
  • 317. Center of iPS Cell Research and Application at Kyoto University in Japan
  • 318. Precision Biologics
  • 319. Pamlico Biopharma Inc.
  • 320. Kite Pharma
  • 321. Index Ventures, LLP
  • 322. Pharmacyclics
  • 323. MedImmune
  • 324. University of Copenhagen
  • 325. ATMI
  • 326. RuiYi Inc.
  • 327. Hyglos GmbH
  • 328. Sartorius Stedium biotech
  • 329. UMN Pharma Inc.
  • 330. Selexys Pharmaceuticals Corp.
  • 331. Barofold
  • 332. CEVEC Pharmaceuticals
  • 333. OncoMed Pharmaceutical, Inc.
  • 334. The National Institutes of health Center for Regenerative Medicine
  • 335. XL-Protein
  • 336. Foundation BioPharma, Inc
  • 337. Xoma Corporation
  • 338. MD Anderson Cancer Center
  • 339. Five Prime Therapeutics, Inc.
  • 340. Biowa
  • 341. Avalanche Biotechnologies, Inc
  • 342. Agennix
  • 343. CSIRO
  • 344. Immutep
  • 345. Nascent Biologics, Inc.
  • 346. LegoChem
  • 347. Eclipse
  • 348. Aptuit
  • 349. ImmuneMed, Inc
  • 350. Antitope Ltd.
  • 351. Inhibrx
  • 352. ContraFect Corporation
  • 353. Pasteuria Bioscience
  • 354. Mesoblast Limited
  • 355. Inspiration Biopharmaeuticals
  • 356. IMMUNE Pharmaceutical
  • 357. Endo Pharmaceuticals USA
  • 358. Alethia Biotherapeutics, Inc.
  • 359. Toyota Tsusho Corporation
  • 360. Oasmia Pharmaceutical
  • 361. Athera Biotechnologies
  • 362. OncoMax
  • 363. Evocatal
  • 364. Nabi Biopharmaceuticals
  • 365. Affitech
  • 366. Vivante GMP Solutions
  • 367. Diamedica Incorporated
  • 368. MODA Technology Partners
  • 369. Virdante Pharmaceuticals
  • 370. Orexigen
  • 371. Kane Biotech Inc.
  • 372. LFB Biomedicaments
  • 373. MicrobixBiosystemsinc.
  • 374. Akorn
  • 375. Aparna Biosciences Corp.
  • 376. RheinMinapharm
  • 377. Cellectis
  • 378. Millennium Pharmaceuticals, Inc.
  • 379. CEVEC Pharmaceuticals
  • 380. UMN Pharma Inc.
  • 381. Foundation BioPharma
  • 382. Translational Sciences, Inc.
  • 383. ARMO Biosciences
  • 384. Elan plc
  • 385. Apexigen
  • 386. BeiGene, Co., Ltd.
  • 387. IMMUNE Pharmaceutical
  • 388. The National Institutes for Health Center for Regenerative Medicine
  • 389. Nabi Biopharamaceuticals
  • 390. JRS
Back to Top